MLchartDataset catalogue

anti-HLA-G/CD3 bispecific antibody JNJ-78306358

Term · Oncology and biomedicine · MLC-T-ONC-010796

A bispecific antibody targeting the tumor-associated antigen (TAA) HLA-G histocompatibility antigen, class I, G (human leukocyte antigen G; HLA-G) and the CD3 antigen found on T lymphocytes, with potential immune checkpoint inhibiting, immunomodulating and antineoplastic activities. Upon administration, the anti-HLA-G/CD3 bispecific antibody JNJ-78306358 targets and binds to both CD3 on cytotoxic T lymphocytes (CTLs) and HLA-G found on HLA-G-expressing tumor cells. This activates and redirects CTLs to HLA-G-expressing tumor cells, which results in the CTL-mediated cell death of HLA-G-expressing tumor cells. HLA-G, an immune checkpoint normally expressed at the maternal-fetal interface, is expressed across multiple tumor types and plays a key role in cancer immune evasion. It inhibits immune responses by binding to its inhibitory receptors on a variety of immune cells, such as natural killer cells (NKs), T and B lymphocytes, and dendritic cells (DCs).

Table 1. Record
IdentifierMLC-T-ONC-010796
FieldOncology and biomedicine
SynonymsT-Cell-redirecting bispecific antibody JNJ-78306358
ReferencesNational Cancer Institute Thesaurus (CC BY 4.0)
Record as JSON
{
  "id": "MLC-T-ONC-010796",
  "term": "anti-HLA-G/CD3 bispecific antibody JNJ-78306358",
  "field": "Oncology and biomedicine",
  "definition": "A bispecific antibody targeting the tumor-associated antigen (TAA) HLA-G histocompatibility antigen, class I, G (human leukocyte antigen G; HLA-G) and the CD3 antigen found on T lymphocytes, with potential immune checkpoint inhibiting, immunomodulating and antineoplastic activities. Upon administration, the anti-HLA-G/CD3 bispecific antibody JNJ-78306358 targets and binds to both CD3 on cytotoxic T lymphocytes (CTLs) and HLA-G found on HLA-G-expressing tumor cells. This activates and redirects CTLs to HLA-G-expressing tumor cells, which results in the CTL-mediated cell death of HLA-G-expressing tumor cells. HLA-G, an immune checkpoint normally expressed at the maternal-fetal interface, is expressed across multiple tumor types and plays a key role in cancer immune evasion. It inhibits immune responses by binding to its inhibitory receptors on a variety of immune cells, such as natural killer cells (NKs), T and B lymphocytes, and dendritic cells (DCs).",
  "synonyms": [
    "T-Cell-redirecting bispecific antibody JNJ-78306358"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/anti-hla-g-cd3-bispecific-antibody-jnj-78306358/"
}

Record 1,906 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.